This study is in progress, not accepting new patients
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study started
- Principal Investigator
- by Lloyd Damon
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Lloyd Damon
Dr. Lloyd Damon is a hematologist and researcher who specializes in blood cancers such as lymphomas and leukemias. Damon studies new treatments for acute myeloid and acute lymphoblastic leukemias. In 1995, he was an early investigator of rituximab, the first monoclonal antibody approved to treat human cancer, specifically lymphoma.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Sponsor
- Alliance for Clinical Trials in Oncology
- ID
- NCT00048958
- Study Type
- Observational
- Participants
- Expecting 9000 study participants
- Last Updated